• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
New study finds youth obesity undertreated, despite new AAP guidelines

New study finds youth obesity undertreated, despite new AAP guidelines

by Truveta staff | Oct 30, 2024 | Research

Truveta Research in collaboration with a Harvard Medical School researcher explore use of obesity treatments in youth before and after new comprehensive guidelines for obesity management were published by the American Academy of Pediatrics (AAP). In a study of 329,357...
SDOH factors like housing and financial stability are key to medication adherence

SDOH factors like housing and financial stability are key to medication adherence

by Truveta Research | Oct 17, 2023 | Research, Research Insights

Social drivers of health (SDOH), such as increased financial struggles and decreased social support, have been shown to be correlated with decreased medication adherence. In this study of patients with type 2 diabetes, we saw an increased rate of medication adherence...
Variation in medication adherence for type 2 diabetes patients

Variation in medication adherence for type 2 diabetes patients

by Truveta Research | Oct 5, 2023 | Research, Research Insights

Annually, over 125,000 deaths are associated with poor medication adherence. The proportion of days covered (PDC) is a common method to measure adherence. When controlling for age, sex, race, and ethnicity, we found similar rates of first year medication adherence for...
Comparative effectiveness of SGLT2i vs. Metformin for first-line antidiabetic treatment

Comparative effectiveness of SGLT2i vs. Metformin for first-line antidiabetic treatment

by Truveta Research | May 9, 2023 | Research, Research Insights

This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes.   Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...

Share this


Recent posts

  • Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
  • Top 5 takeaways from Truveta Symposium 2025
  • Women’s health: Pain medication remains rare for women receiving IUDs

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Get started

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Interested in learning more?

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice